ORIGINAL ARTICLE

Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection

Choong Tat Keng,1 Ching Wooen Sze,2 Dahai Zheng,1 Zhiqiang Zheng,1 Kylie Su Mei Yong,1 Shu Qi Tan,3 Jessica Jie Ying Ong,1 Sue Yee Tan,1 Eva Loh,4 Megha Haridas Upadya,2 Chik Hong Kuick,4 Hak Hotta,5 Seng Gee Lim,6,7 Thiam Chye Tan,3,8 Kenneth T E Chang,4,8 Wanjin Hong,1 Jianzhu Chen,9,10 Yee-Joo Tan,1,2 Qingfeng Chen1,2,9

ABSTRACT

Objective HCV infection affects millions of people worldwide, and many patients develop chronic infection leading to liver cancers. For decades, the lack of a small animal model that can recapitulate HCV infection, its immunopathogenesis and disease progression has impeded the development of an effective vaccine and therapeutics. We aim to provide a humanised mouse model for the understanding of HCV-specific human immune responses and HCV-associated disease pathologies.

Design Recently, we have established human liver cells with a matched human immune system in NOD-scid Il2rg−/− (NSG) mice (HIL mice). These mice are infected with HCV by intravenous inoculation, and the pathologies are investigated.

Results In this study, we demonstrate that HIL mouse is capable of supporting HCV infection and can present some of the clinical symptoms found in HCV-infected patients including hepatitis, robust virus-specific human immune cell and cytokine responses as well as liver fibrosis and cirrhosis. Similar to results obtained from the analysis of patient samples, the human immune cells, particularly T cells and macrophages, play critical roles during the HCV-associated liver disease development in the HIL mice. Furthermore, our model is demonstrated to be able to reproduce the therapeutic effects of human interferon alpha 2a antiviral treatment.

Conclusions The HIL mouse provides a model for the understanding of HCV-specific human immune responses and HCV-associated disease pathologies. It could also serve as a platform for antifibrosis and immune-modulatory drug testing.

INTRODUCTION

With >175 million people infected globally, the HCV represents a major health concern worldwide.1 Many of these patients with the infection often progress to develop hepatitis, liver fibrosis, cirrhosis and hepatocellular adenoma or carcinoma.2 A major obstacle in the development of vaccine and antiviral therapy arises from the fact that HCV tropism is restricted to humans. Chimpanzees are currently the most complete model that can support the complete HCV life cycle and recapitulate the host responses observed in human patients, but limitations such as low chronic infection rate, poor demonstration of liver fibrosis, high cost and ethical concerns have limited their usage for HCV research.1,4

The lack of a small animal model that can recapitulate the viral infection and liver pathogenesis observed in human patients has limited progress in the understanding of the viral–host interactions, HCV-specific immune responses and progression of
the diseased pathology as well as in the development of vaccines and therapeutics. The current mouse models for HCV infection are mostly transgenic mouse models that were genetically modified to allow virus infection to mouse hepatocytes or to enhance the transplantation of mature human hepatocytes. The immunodeficient Alb-uPA/SCID mouse with the repopulation of mature human hepatocytes was the first mouse model to demonstrate successful HCV infection and replication in vivo. The Fah-Rag2-γC null mice were later developed to solve some of the limitations of the Alb-uPA/SCID mice such as the fragility or excessive mortality of the mice. These mouse models can be efficiently infected with HCV but did not develop clinical symptoms seen in HCV-infected patients.

Recently, the Apc8-Hsc/Hep Balb/C Rag2-γC-null and HLA-A2 NOD-SCid Il2rg−/− (NSG) mouse models were developed with both human immune system and liver cells. The transplantation of liver progenitor cells in this transgenic mouse requires extra treatment to induce liver cell death. Both mouse models were shown to be able to support hepatitis virus infection with liver inflammation, hepatitis and fibrosis. Previously, we demonstrated a simple one-step engraftment of human liver cells and a matching human immune system in the same NSG mouse (HIL mice), without the need for transgenic modification or drug treatment. In this study, we showed that the HIL mice can support HCV infection, liver inflammation, HCV-specific human immune responses, as well as liver fibrosis. Antiviral treatment using interferon alpha-2a (IFNα-2a) was able to block the progression of the HCV-associated liver pathogenesis.

**METHODS**

**Human fetal liver progenitor stem cells**

Human CD34+ cells were freshly isolated from aborted fetuses at 15–23 weeks of gestation, in accordance with the institutional ethical guidelines of the KK Women’s and Children’s Hospital, Singapore. Fetal liver tissues were processed as described previously. CD34+ cells were purified by magnetic-activated cell sorting using the EasySep CD34-positive selection kit (Stemcell Technologies) under sterile conditions, following manufacturer’s protocol. The purity of the CD34+ cells was 90–99%

More detailed materials and methods can be found in online supplementary material.

**RESULTS**

**HCV infection leads to liver leucocyte infiltration and lesions in HIL mice**

Good human immune cell reconstitution with a mean of ~40% was reproducibly obtained for HIL mice (see online supplementary figure S1A and S1B). Five to ten per cent of hepatocytes were stained positive for human albumin (hALB) in HIL mouse liver while no staining was observed in NSG mouse (see online supplementary figure S1C). Eight-week-old HIL mice have serum hALB levels with a mean value of 26.4 ng/mL (see online supplementary figure S1D). To analyse the maturation status of human hepatocytes in HIL mice, human epidermal growth factor receptor (hEGFR) cells were purified from perfused livers and assayed for hepatocyte markers. Similar to human adult hepatocytes, these hEGFR+ cells have high mRNA levels of human hepatocyte maturation markers like keratin 18 (CK18), tyrosine aminotransferase (TAT), alpha-1 antitrypsin, trypthphan 2,3-dioxigenase and cytochrome P450 (see online supplementary figure S1E). The immunofluorescent staining confirmed that >95% of hEGFR+ cells expressed hALB, yet only ~50% of hEGFR+ cells expressed the maturation markers CK18 and TAT (see online supplementary figure S1F).

To confirm that the purified hEGFR+ cells accurately represent all human hepatocytes in livers of HIL mice, liver sections were stained with antibodies specific against hALB or hEGFR. Coexpression of hALB and hEGFR could be seen in >95% of hepatocytes that expressed either hALB or hEGFR (see online supplementary figure S1G). Collectively, these results show the presence of mature human hepatocytes in HIL mice and that hEGFR can be used effectively as a marker for sorting out human hepatocytes from HIL mice.

Ten-week-old HIL mice were inoculated with 1×10⁶ FFU/mL of j6/JFH-1 HCV (genotype 2a) viruses. Although we could not detect HCV RNA directly from the sera or livers of HCV-infected HIL mice as they were below our detection limit, we detected HCV RNA in the hEGFR+ cells isolated from HCV-infected HIL mice, while no HCV RNA was detected in the hEGFR+ cells from mock-infected mice. An average of 321 HCV RNA copies per 100 ng of total RNA was detected in the infected mice 2 weeks post-infection (figure 1A). For the 5 weeks post-infection group, the level of virus appears to have increased as an average of 944.2 HCV RNA copies per 100 ng of total RNA was detected in the infected mice (figure 1A). However, the difference between 2 and 5 weeks is not statistically significant, and there is substantial variation in the HCV RNA levels between mice, thus further studies are needed to determine the temporal expression of viral RNA during the infection cycle in infected HIL mice. Consistently, HCV proteins were detected in the enriched hEGFR hepatocytes using HCV-infected patient serum in both TAT+ mature and TAT–immature cells (see online supplementary figure S2A). Previous studies also showed that HCV could infect immature hepatocytes or induced pluripotent stem cells-derived hepatocyte-like cells that resemble fetal hepatocytes more than adult hepatocytes, as they expressed all the necessary HCV entry factors. More importantly, dsRNA was detected only in the CK18+ mature hepatocytes using immunofluorescence, further confirming that active viral replication occurred in the liver of HCV-infected HIL mice (figure 1B). In addition, HCV core antigen was detected in situ in ~10% of hALB+ hepatocytes in the liver of HCV-infected HIL mice but not in the mock-infected mice (figure 1C). All these results show that HCV can infect and replicate in the human hepatocytes of HIL mice.

In the livers of HIL mice that were infected with HCV for 0, 1, 3, 5 or 9 weeks, increasing leucocyte infiltration and progressive lesions formation were observed over the course of infection (figure 1D). There was no infiltration or lesions found in the livers of mock-infected HIL mice. At the early stage of infection (<6 weeks), the infiltrated areas of human CD45+ cells correlated well with areas positive for hALB, suggesting the target of initial leucocyte infiltration is human hepatocytes (see online supplementary figure S2B). As only ~10% of the hALB+ cells were infected with HCV, it seems like leucocyte infiltration has also occurred rapidly in the surrounding bystander cells. Consistent with the progressive liver damage observed in H&E staining, serum alanine aminotransferase (ALT) level were also elevated in HIL mice over the course of HCV infection (figure 1E). Overall, HIL mice are able to support HCV infection that leads to immune cell infiltration and progressive liver damage.

**HCV infection of HIL mice leads to activation of hepatic stellate cells and upregulation of fibrotic genes with consequential liver fibrosis and cirrhosis**

To study the progression of liver pathology, the livers of mock-infected and HCV-infected HIL mice were harvested at week 0–9 post-infection for histological examination. In the livers, Keng CT, et al. Gut 2015;0:1–10. doi:10.1136/gutjnl-2014-307856
there were nodule fibrosis at 3 weeks post-infection, fibrosis with numerous septa at 5 weeks post-infection and severe scarring and cirrhosis with nodular structures forming as a result of inflammation at 9 weeks post-infection (figure 2A and see online supplementary figure S3A). No liver pathology was observed in the mock-infected HIL mice (figure 2A). A representative list of HCV-infected or mock-infected HIL mice with their respective liver disease scoring is provided in online supplementary table S1. Further analysis showed that there was no inflammation or lesions in other organs (lung, kidney, heart and intestines) of mock-infected or HCV-infected HIL mice, indicating that the pathology observed in the HCV-infected HIL mice is liver-specific (see online supplementary figure S3B). In addition, there is no cell infiltration or damage in HCV-infected Balb/c and NSG mice, which do not have human cells (see online supplementary figure S3C). We previously showed that NSG mice engrafted with human cord blood CD34+ cells (CB mice) developed human immune system but had few human hepatocytes. HCV infection of CB mice did not result in liver infiltration and lesions (see online supplementary figure S3C), suggesting that both the human immune system and hepatocytes are required to recapitulate the liver pathogenesis observed in HCV-infected patients. HCV infection in humans is known to lead to the activation of hepatic stellate cells, which contributes towards the progression of fibrosis. As shown by the expression of alpha smooth muscle actin, activation of hepatic stellate cells occurred in HCV-infected but not in mock-infected HIL mice (figure 2B). Gene expressions of collagen 1A1 (Col1A1) and tissue inhibitor of matrix metalloproteinases 1 (TIMP1) are known to be elevated in activated hepatic stellate cells for attenuation of liver fibrosis. Consistently, the expression of both human and mouse Col1A1 and TIMP1 genes were upregulated in the livers of the HCV-infected HIL mice (figure 2C, D). In addition, high...
levels of human TIMP1 and TIMP2 proteins were detected in the sera of the HCV-infected mice (Figure 2E). These results show that the liver fibrosis and cirrhosis in the chimeric liver of HCV-infected HIL mice resulted from activation of hepatic stellate cells and upregulation of both human and mouse fibrogenic genes.

**HCV infection induces intrahepatic human immune cell infiltration and cytokine responses in HIL mice**

To dissect the intrahepatic immune cells infiltration, absolute cell number counts of hepatic mononuclear cells and flow cytometry quantitative analysis were performed. There was a slight increase in human CD45+ leucocytes in the livers of HCV-infected HIL mice at 3–7 weeks post-infection, while the increase at 9 weeks post-infection was almost threefold (Figure 3A). There was no significant cell number change in the mock-infected mice (Figure 3A). Among these infiltrated human leucocytes, hepatic human T cells (CD45+CD3+) (Figure 3B, C) and macrophages (CD45+CD14+) (Figure 3B, D) increased most significantly, which is consistent with the observations in HCV-infected patients. The kinetics of human cell infiltration was correlated with the development and severity of liver damage (Figure 1D), fibrosis and cirrhosis (Figure 2A), suggesting that the human immune system is involved in the disease development. To assay human cytokine responses to HCV infection in HIL mice, serum human IFNγ and interleukin (IL)6 levels were monitored over the course of infection. Both human IFNγ (Figure 3E) and IL-6 (Figure 3F) levels increased gradually over the course of infection reaching an average of $440 \pm 181$ and $234 \pm 109$ pg/mL, respectively, at 9 weeks post-infection. In contrast, human IFNγ and IL-6 levels were barely detectable in HCV-infected CB mice (see online supplementary figure S3D and S3E). These results show that the human immune system in HIL mice are able to generate robust human cellular and cytokine responses to HCV infection.

**The human inflammatory cytokine profiles in HCV-infected HIL mice are similar to human**

To analyse the inflammatory human cytokine profiles in the HCV-infected HIL mouse model, sera from HIL mice were assayed for another 28 inflammatory cytokines. At 9 weeks post-infection, 10 cytokines showed elevated levels in the sera of HCV-infected HIL mice (Figure 3G), while 7 of them (B lymphocyte chemoattractant (BLC), eosinophil chemotactic protein 2, I-309, IL-8, monocyte chemotactic protein-1 (MCP1), monocyte chemotactic protein-1 beta (MIP1b) and tumour necrosis factor receptor II (TNF-RII)) were significantly upregulated. Consistently, BLC, IL-8, MCP1, MIP1b and TNF-RII were also found to be upregulated in HCV-infected patients. These results show that the proinflammatory human cytokine responses in HCV-infected HIL mice are similar to those in infected humans.

**HCV infection elicits robust virus-specific immune cell responses in HIL mice**

To investigate the presence of HCV-specific human immune responses in HIL mice, splenocytes from HCV-infected and mock-infected HIL mice at 9 weeks post-infection were analysed. A drastic increase of the spleen size (Figure 4A) and splenocyte numbers was observed in HCV-infected HIL mice with a mean of $4.48 \times 10^8$ cells compared with $6.5 \times 10^7$ cells in mock-infected mice (Figure 4B). In the mock-infected HIL mice, the majority of the human leucocytes in spleen were CD19+ B cells with a mean of 71.0%, while CD3+CD4+ and CD3+CD8+ T cells were represented by a mean of 6.1% and 6.2%, respectively (Figure 4C, left). In HCV-infected mice, human CD3+CD4+ and CD3+CD8+ T cells expanded and became predominant with a mean of 52.4% and 19.6%, respectively (Figure 4C, right). In terms of total cell number, there was a significant increase of $\sim$58-fold in CD3+CD4+ T cells and $\sim$19-fold in CD3+CD8+ T cells in HCV-infected HIL mice (Figure 4D). A relatively smaller increase of approximately
twofold in CD19+ B cells, CD56+ natural killer cells and CD14+ macrophages were observed (figure 4D). These data suggest that CD4+ and CD8+ T cell responses are predominant in HIL mice during HCV infection, which is consistent to human.

To test the levels of human HCV-specific T cell responses, splenocytes from HCV-infected and mock-infected HIL mice were used for human IFNγ ELISPOT assay. Splenocytes were stimulated with a mixture of 16 synthetic overlapping peptides covering the HCV core protein or SARS synthetic peptides, which served as a non-specific stimulation control. Phorbol 12-myristate 13-acetate (PMA) and ionomycin stimulation served as positive control. For splenocytes from HCV-infected HIL mice, the numbers of IFNγ-producing spots forming units were detected at a mean of 1400/million cells in HCV peptide-stimulated group, which is significantly higher than the SARS peptide-stimulated group or non-stimulated group (figure 4E). Splenocytes from mock-infected mice did not respond to the peptide stimulations (figure 4E). This result demonstrates that robust HCV-specific T cell responses are present in HCV-infected HIL mice.

Sera from HCV-infected HIL mice were tested for the presence of anti-HCV human antibodies by immunofluorescence and ELISA. HCV-specific human IgG was detected in the sera from ∼20% of HCV-infected HIL mice by staining HCV-infected Huh7.5 cells (see online supplementary figure S4A). Uninfected Huh7.5 cells were stained negative using the same sera. ELISA also showed that there were specific anti-HCV.
NS3 antibodies in the sera of HCV-infected HIL mice (see online supplementary figure S4B). This result indicates the presence of HCV-specific human antibody responses in the HCV-infected HIL mice.

Human T cells and macrophages play critical roles in inflammation, fibrosis development and human cytokine response in HCV-infected HIL mice

To investigate the roles of specific human immune cell populations during HCV infection, we performed antibody-based depletion of human CD4+, CD8+ T cells and CD14+ macrophages in HIL mice prior to HCV infection. The effect of systematic targeted cell depletion was shown (see online supplementary figure S5). Eight weeks after HCV infection, extensive liver scarring with leucocyte infiltration and fibrosis was observed in phosphate buffered saline (PBS)-treated HIL mice (ctrl) (figure 5A). For the HIL mice that were depleted of CD4+ T cells or CD8+ T cells, no obvious liver scarring, leucocyte infiltration or fibrosis were observed after HCV infection (figure 5A). When HIL mice were depleted of CD14 macrophages, only limited leucocyte infiltration and slight collagen deposition were observed (figure 5A). Serum levels of human IFNγ were dramatically reduced in the depletion groups from a mean level of 431.8 pg/mL in control mice to 0 pg/mL in CD4 T cells-depleted mice, 12.1 pg/mL in CD8 T cells-depleted mice and 3.2 pg/mL in CD14 macrophage-depleted mice (figure 5C). These results indicate that both T cells and macrophages play critical roles in the HCV-induced liver pathogenesis. IFNγ are known to be mainly produced by T cells while macrophages are the main sources of IL-6.30–32 The depletion of either the human T cells or macrophages resulted in a drastic reduction of both human IFNγ and IL-6 levels, suggesting that there are interplays between the T cells and macrophages in the immune responses to HCV infection. However, T cell depletion did not significantly affect the level of HCV RNA in hEGFR+ cells isolated from HIL-infected mice (figure 1A), which suggest that successful viral infection alone is not sufficient to cause liver disease and is consistent with the importance of immunemediated pathogenesis in HCV infection.33

IFNα-2a treatment blocks the progression of liver disease and antiviral human immune responses in infected HIL mice

Human IFNα-2a has been used in clinical treatment of HCV-infected patients as it is known to inhibit HCV replication and its subsequent disease progression.34 To investigate whether our HIL model can reproduce the therapeutic effect of IFNα-2a against HCV infection, we performed intramuscular injections of recombinant IFNα-2a in the HCV-infected HIL mice three times a week. Eight weeks after HCV infection, the PBS-treated HIL mice developed severe liver leucocyte infiltration and 179.8 pg/mL in control mice to 0 pg/mL in CD4 T cells-depleted mice, 12.1 pg/mL in CD8 T cells-depleted mice and 3.2 pg/mL in CD14 macrophage-depleted mice (figure 5C). These results indicate that both T cells and macrophages play critical roles in the HCV-induced liver pathogenesis. IFNγ are known to be mainly produced by T cells while macrophages are the main sources of IL-6.30–32 The depletion of either the human T cells or macrophages resulted in a drastic reduction of both human IFNγ and IL-6 levels, suggesting that there are interplays between the T cells and macrophages in the immune responses to HCV infection. However, T cell depletion did not significantly affect the level of HCV RNA in hEGFR+ cells isolated from HIL-infected mice (figure 1A), which suggest that successful viral infection alone is not sufficient to cause liver disease and is consistent with the importance of immunemediated pathogenesis in HCV infection.33

IFNα-2a treatment blocks the progression of liver disease and antiviral human immune responses in infected HIL mice

Human IFNα-2a has been used in clinical treatment of HCV-infected patients as it is known to inhibit HCV replication and its subsequent disease progression.34 To investigate whether our HIL model can reproduce the therapeutic effect of IFNα-2a against HCV infection, we performed intramuscular injections of recombinant IFNα-2a in the HCV-infected HIL mice three times a week. Eight weeks after HCV infection, the PBS-treated HIL mice developed severe liver leucocyte infiltration and
Clinical HCV strain can induce liver pathogenesis in HIL mice

To investigate whether the HIL mouse model can be used for the study of different genotypes of HCV strains, we inoculated the mice with an HCV clinical strain (CS) of genotype 3a. We were able to observe similar leucocyte infiltration and fibrosis in the HCV CS-infected HIL mice as those infected by J6/JFH-1 (see online supplementary fig S6A). The immunostaining of human CD45+ cells confirmed the hepatic infiltration of human leucocytes, which was not observed in the mock-infected mice (see online supplementary figure S6B). These data showed that HIL mice can reproduce liver pathogenesis induced by direct inoculation with clinical isolates from HCV-infected patients.

**DISCUSSION**

In most of the published humanised mouse models such as uPA/SCID or Fah-Rag2-γC-null that were transplanted with human hepatocytes, they were able to support HCV infection but failed to develop liver fibrosis, which may be due to the absence of a functional immune system. The recent AFC8-HSC/Hep Balb/C Rag2-γC-null mouse model that has human immune system and hepatocytes were able to develop fibrosis after HCV infection; however, it requires additional drug treatment to induce mouse hepatocyte apoptosis. Our HIL mouse model abolishes the need for the induction of mouse hepatocyte apoptosis or surgery, thus has better survival rate upon human cell transplantation. In addition, the NSG mouse used in this work are known to support better human immune cell engraftment and functions than Balb/C Rag2-γC-null mice due to its defective mouse phagocyte activity. In particular in our model, NSG mouse needs only 2×10⁵ CD34+ fetal liver cells to achieve similar human cell engraftment compared with other models that require 5–10 times more cells. In addition, mature human hepatocytes were clearly detected in the hEGFR⁺ cells isolated from HIL mice. In this study, J6/JFH-1 (genotype 2a) and serum from an HCV-infected patient (genotype 3) both yielded similar disease outcome in HIL mice. In current model, the level of viral RNA in the blood of the infected mice was too low to be detected. However, a significant level of HCV RNA was detected when hEGFR⁺ cells were enriched from the infected liver. Consistently, HCV protein expression was detected in ~10% of the human hepatocytes. A similar observation was reported in the AFC8-HSC/Hep model where no serum viraemia was observed and only little viral RNA was detected in the livers from about 50% of mice at 1–4 months post-infection. In contrast, significant viraemia was achieved in the human liver-uPA/SCID or Fah-Rag2γC null mouse models. One possible reason for this difference is that the chimeric level of human hepatocyte, which is derived from fetal hepatic progenitor cells, in HIL mice is <10% compared with the >50% adult hepatocyte engraftment in the uPA/SCID or Fah-Rag2γC null mouse models. Notably, in human patients, there are also occult HCV infection cases where the low level of viral replication is not detectable by commercial kits. Patients with occult HCV viraemia were shown to develop liver inflammation and fibrosis. Interestingly, despite the low levels of HCV infection, infected HIL mice consistently developed severe liver damage, fibrosis and cirrhosis. In view of the relatively low reconstitution of human hepatocytes in HIL mice, our results also suggest that infection in only a small proportion of liver cells is sufficient to induce severe disease outcome. In addition to the expression of viral proteins and RNA, the occurrence of fibrosis, while no leucocyte infiltration or fibrosis was detected in the IFNα-2a-treated group (figure 6A). In the mock-infected PBS-treated or the mock-infected IFNα-2-treated HIL mice, there was also no inflammation or fibrosis observed (figure 6A). The production of human IFNγ in HCV-infected HIL mice was significantly lower in the IFNα-2a-treated group compared with PBS control (figure 6B). However, the serum levels of human IL-6 in the IFNα-2a-treated group remained elevated (figure 6C). Notably, the serum levels of human IL-6 also increased slightly in the control group with mock infection and IFNα-2a treatment while IFNγ remained unelevated (figure 6B, C). The significance of this increase is not clear, but there have been reports that the IFNα-2a treatment in HCV-infected patients resulted in an elevation of serum IL-6 level. Serum ALT levels in HCV-infected mice were also significantly suppressed after IFNα-2a treatment (figure 6D), indicating efficient blocking of liver disease progression. Consistently, detection of HCV RNA performed at 1 and 4 weeks post-IFNα-2a treatment (2 and 5 weeks post-infection, respectively) showed reduction of HCV RNA copy numbers especially at 4 weeks post-IFNα-2a treatment, where >50% reduction was observed. An average of 325.6 copy/100 ng of total RNA was detected in the PBS-treated group compared with 140.4 copy/100 ng of total RNA in the IFNα-2a treated group (figure 6E). Hence, our data clearly reproduce the therapeutic effect of the antiviral treatment of IFNα-2a and strongly suggest that HIL mouse is a useful platform for drug screening and testing.
robust HCV-specific human T and B cell responses and successful antiviral drug treatment also provide independent evidence of HCV infection in HIL mice. However, the degree of chronicity of HCV infection in HIL mice needs further investigation. The chronic inflammation and immune responses in HCV-infected patients are reported to contribute to the development of the liver disease.44–46 HIL mouse successfully recapitulates many features of the disease progression in HCV-infected patients by showing intrahepatic human immune cell infiltration, HCV-specific human immune responses, as well as liver fibrosis and cirrhosis. To our knowledge, this is the first study to report significant serum levels of human cytokine responses to HCV infection in a mouse model. This may be due to the better human cell reconstitution and function in NSG mice. In view of the inflammatory cytokine profiles, notably the cytokines found significantly elevated in HCV-infected HIL mice are the similar cytokine signatures of HCV-infected patients.24–29 These results clearly demonstrate that HIL mice are able to produce cytokine and chemokine networks, which closely resemble those described for human infection, to regulate the trafficking and functions of human immune cells responding to HCV infection.

It remains unclear whether the liver diseases caused by HCV are due to the death of infected or healthy cells and how immune system is engaged. Notably, we showed that the inflammation and cell infiltration were initially restricted to human areas in liver but gradually spread and affected non-human areas, and caused massive damage in the whole liver. This probably was due to the production of high levels of human proinflammatory cytokines (eg, IFNγ), which are known to have cytotoxic effects to hepatocytes, resulting in sustained liver damage and eventually in liver cirrhosis.47 48 Furthermore, the depletion of either the human T cells or macrophages resulted in a dramatic decrease in pathology and human cytokine responses, which reveals that T cells and macrophages are main effector cells in pathology and there are mechanisms regulating their cross-talks. Interestingly, non-HCV-specific T cells appears to be much more abundant than the HCV-specific ones in the liver infiltrate of chronic HCV-infected patients.49 Whether or not these unconventional T cells play a role in mediating pathogenesis could be further investigated using the HIL mice. Further investigation on HIL mouse model will help to uncover new mechanisms underlying human specific antiviral immunity and pathogenesis.

Our work demonstrated that HCV strains of two different genotypes can both lead to severe liver diseases in the HIL mouse model. Furthermore, the drug testing of IFNα-2a in HIL mice successfully reproduced the therapeutic effects seen in patients.35 36 As HCV exist as variants or so-called quasispecies of high complexity and diversity, it has been noticed that drug resistant develops easily and renders the direct-acting antiviral drugs ineffective even in the presence of IFNα.50 In the quest to achieve an effective IFN-free regimen, extensive research is now focused on the development of novel drugs like host-targeting agents that target specific host factors essential for HCV replication. Hence, the HIL mouse could be useful in future testing of new drugs or combination of drugs for hepatitis C treatment.

Figure 6 Interferon alpha 2a (IFNα-2a) treatment prevents disease progression in mice infected with HCV. HIL mice were treated with IFNα-2a three times a week starting from 1 week post mock-infection or HCV-infection (n=5 mice per group). Livers and sera were harvested at 8 weeks after infection for histology, ELISA and alanine aminotransferase (ALT) measurement. (A) Representative liver stains of H&E to visualise leucocyte infiltration (top row) and stains for Sirius red/fast green to visualise collagen deposition (bottom row) are shown. (B) Serum levels of human IFNγ were determined by ELISA. (C) Serum levels of human interleukin-6 were determined by ELISA. (D) Serum ALT levels of HIL mice from different treatment groups are represented in the graph. (E) Human epidermal growth factor receptor+ cells purified from livers of mock-infected, HCV-infected HIL mice treated with phosphate buffered saline (PBS) or IFNγ-2a (indicated by *) at 2 and 5 weeks post-infection (1 and 4 weeks post-IFNγ-2a treatment, respectively) and analysed for HCV RNA by RT-PCR (n=5 mice per group). Data represent means±SEM.
Author affiliations
1 Institute of Molecular and Cell Biology, Singapore, Singapore
2 Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
3 Department of Obstetrics & Gynaecology, KK Women’s and Children’s Hospital, Singapore, Singapore
4 Department of Pathology and Laboratory Medicine, KK Women’s and Children’s Hospital, Singapore, Singapore
5 Division of Microbiology, Kobe University Graduate School of Medicine, Hyogo, Japan
6 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
7 Department of Gastroenterology and Hepatology, National University Health System, Singapore, Singapore
8 Duke-NUS Graduate Medical School, Singapore, Singapore
9 Interdisciplinary Research Group in Infectious Diseases, Singapore-Massachusetts Institute of Technology Alliance for Research and Technology, Singapore, Singapore
10 The Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

Acknowledgements
We thank Antonio Bertoletti (Duke-NUS, Singapore) for giving critical comments and advice and C. M. Rice (Rockefeller University, USA) for providing the pFL-B6/JFH1 and HuH7.5 cells.

Contributors
CTK and CWS contributed equally. QC, CT, Y-JT designed research; CTK, CZ, CWS performed research; CTK, CZ drafted the manuscript. QC, CT, Y-JT edited and revised the manuscript.

Competing interests
None declared.

Patient consent
Obtained.

Ethics approval
SingHealth Centralised Institutional Review Board B.

Provenance and peer review
Not commissioned; externally peer reviewed.

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
<table>
<thead>
<tr>
<th>Page</th>
<th>Reference</th>
</tr>
</thead>
</table>
Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection

Choong Tat Keng, Ching Wooen Sze, Dahai Zheng, Zhiqiang Zheng, Kylie Su Mei Yong, Shu Qi Tan, Jessica Jie Ying Ong, Sue Yee Tan, Eva Loh, Megha Haridas Upadya, Chik Hong Kuick, Hak Hotta, Seng Gee Lim, Thiam Chye Tan, Kenneth T E Chang, Wanjin Hong, Jianzhu Chen, Yee-Joo Tan and Qingfeng Chen

Gut published online July 6, 2015

Updated information and services can be found at:
http://gut.bmj.com/content/early/2015/07/06/gutjnl-2014-307856

These include:

Supplementary Material
Supplementary material can be found at:
http://gut.bmj.com/content/suppl/2015/07/06/gutjnl-2014-307856.DC1

References
This article cites 50 articles, 15 of which you can access for free at:
http://gut.bmj.com/content/early/2015/07/06/gutjnl-2014-307856#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (353)
Hepatic cancer (474)
Cirrhosis (331)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/